Altravax
Altravax, a US biopharmaceutical firm, innovates novel vaccines for infectious diseases using its proprietary Immunogen Optimization System™.
Founded
2009Altravax, a US biopharmaceutical firm, innovates novel vaccines for infectious diseases using its proprietary Immunogen Optimization System™.
Founded in 2009, Altravax is a privately held biopharmaceutical company headquartered in North Dakota with research facilities in Sunnyvale, California. The company's core mission is to discover and develop novel products to combat infectious diseases and other health conditions. Utilizing its proprietary Immunogen Optimization System™ (IOS), Altravax aims to create innovative vaccines or enhance existing ones to address unmet medical needs. The company focuses on a robust pipeline of vaccine candidates targeting various infectious diseases.
Notable affiliated individuals include key scientists and researchers specializing in immunology and vaccine development. Altravax has attracted investment from private equity firms and strategic partners within the biopharmaceutical industry. The company’s significant achievements include advancing multiple vaccine candidates through preclinical stages and securing patents for its IOS technology. Altravax's impact lies in its potential to revolutionize vaccine development, offering new solutions for global health challenges.
Companies similar to Altravax include Agilvax, Iaso Therapeutics, VitriVax and Alphavax.
Altravax was founded in 2009.
Altravax's headquarters is located in Sunnyvale, CA, US.
Altravax's most recent funding round was for $2M (USD) in November 2009.
As of Nov 30, 2009, Altravax has disclosed funding of $2M (USD). Undisclosed round amounts are excluded.
Altravax has 11 employees as of Feb 5, 2024.
Alphavax
alphavax.com
